Payden Low Duration Fund - Charts and Resources

Data discoverability for Payden Low Duration Fund updated as of 2025-06-25.

2025-06-25

Fund Overview

JBE5Q1GFOJSHZAIQ1855
Search FIGI
Fund NamePayden Low Duration FundFund LEIFund FIGI

Fund Metrics

Key metrics and portfolio distribution for the fund's structured product holdings. Note: These metrics only reflect the holdings we track and may not represent the fund's complete portfolio.

Portfolio Summary

Total Value
$24,683,652
Number of Holdings
9
Asset Types
1
Average Position Size
$2,742,628

Asset Distribution

AUTO
100.0%
Filing Date
Jun 24, 2025
Report Date
Oct 30, 2025

Auto ABS Holdings

Explore a list of auto abs deals held by this fund, sourced directly from the most recent NPORT-P filings on EDGAR SEC.gov. The funds in this table should have a reporting period end date in the future which means the holdings are current as of the most recent filing.
DealFiling DateTranchesTotal ValueReporting PeriodDistress Signals
CARMX 2025-22025-06-25$5,623,2182025-10-31
CRVNA 2024-P22025-06-25$3,183,3592025-10-31
CARMX 2024-32025-06-25$2,903,8322025-10-31
SDART 2024-22025-06-25$2,539,2242025-10-31
CRVNA 2024-P42025-06-25$2,414,9902025-10-31
CARMX 2024-42025-06-25$2,318,5242025-10-31
CRVNA 2025-P12025-06-25$2,014,0192025-10-31
COPAR 2024-12025-06-25$1,924,0452025-10-31
CRVNA 2021-P32025-06-25$1,762,4432025-10-31
DealTranchesTotal Value
CARMX 2025-2
2025-10-31
$5,623,218
CRVNA 2024-P2
2025-10-31
$3,183,359
CARMX 2024-3
2025-10-31
$2,903,832
SDART 2024-2
2025-10-31
$2,539,224
CRVNA 2024-P4
2025-10-31
$2,414,990
CARMX 2024-4
2025-10-31
$2,318,524
CRVNA 2025-P1
2025-10-31
$2,014,019
COPAR 2024-1
2025-10-31
$1,924,045
CRVNA 2021-P3
2025-10-31
$1,762,443
* This table is not yet exhaustive. It is a new feature and contains only the funds we have found so far based on the tranche identifiers we know about. We are still working on it!
* Reporting Period represents the reporting period end date from the NPORT-P filing.
* For full disclosures, please visit our disclosures page.